A new framework known as Behçet's spectrum disorders (BSD) is offering clinicians a mechanism-based approach to diagnose and treat children with unexplained inflammatory symptoms that resemble Behçet's disease but do not meet traditional diagnostic criteria. Originally introduced in 2020, the BSD concept has now been formalized in a review published in the World Journal of Pediatrics (DOI: 10.1007/s12519-026-01035-4) on June 23, 2026, by researchers at Peking Union Medical College Hospital in Beijing.
Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Additionally, several monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms yet require different treatments. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering. The BSD framework aims to address this by grouping these conditions based on shared inflammatory pathways rather than symptom clusters alone.
The researchers propose a two-tier classification: 'core BSD' for monogenic diseases that directly disrupt NF-κB or JAK-STAT signaling, including HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and converge on Behçet's-defining inflammatory circuits. 'Peripheral BSD' includes polygenic or multifactorial entities such as recurrent aphthous stomatitis, PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap or indirect pathway engagement.
A major highlight of the review is the identification of NF-κB and JAK-STAT as two central inflammatory hubs that serve as common denominators across the entire spectrum, providing a rational basis for grouping these diverse disorders. The authors also carefully delineate exclusion criteria, distinguishing true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations, thereby sharpening diagnostic boundaries. Importantly, the framework does not replace existing Behçet's disease criteria but offers a mechanism-oriented lens to prioritize genetic testing in early-onset or atypical pediatric cases, significantly reducing diagnostic odysseys.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies such as IL-1, TNF, or JAK inhibitors for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism-based trials. Ultimately, this framework empowers pediatricians to move beyond trial-and-error management towards precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment.
'We're not saying these are all the same disease—they're not,' the authors said. 'But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why.' They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
